Document is current

Article History

Received: 5 February 2024

Accepted: 19 December 2024

First Online: 22 January 2025

Declarations

:

: This study was performed with dissociated data, therefore Ethics approval and consent were not applicable.

: Not applicable.

: IdR has received funding support from the Instituto de Salud Carlos III (ISCIII) grant FI20/00215. MA has received funding support from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI22/01403. AR has received funding support from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grants AC17/00100, PI19/01301, PI22/01403 and PMP22/00022, and from the European Union Joint Programme – Neurodegenerative Disease Research (JPND) Multinational research projects on Personalized Medicine for Neurodegenerative Diseases/Instituto de Salud Carlos III grant AC19/00097. AR is member of scientific advisory board of Landsteiner Genmed and Grifols SA and has stocks of Landsteiner Genmed. MB has received funding support from Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant grant PI17/01474; has received consulting fees from Grifols, Araclon Biotech, Roche, Biogen, Lilly, Merck, Zambon and Novo-Nordisk; and has participated on Advisory Boards from Grifols, Roche, Lilly, Araclon Biotech, Merck, Zambon, Biogen, Novo-Nordisk, Bioiberica, Eisai, Servier, Schwabe Pharma, Lighthouse Pharma. MM has received funding support from Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - Una manera de hacer Europa) grant PI19/00335; has received travel support to attend scientific meeting from F. Hoffmann-La Roche Ltd, and has participated in the Spanish Scientific Advisory Board of Biomarkers of Araclon Biotech-Grífols.All other authors declare no potential competing interests.